Compare Merck & Co., Inc. (MRK) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs VICI Properties Inc — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while VICI Properties Inc trades at $26.08 (market cap $28.61B). The key difference: Merck & Co., Inc. is far larger — about 11.2× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| MRK | VICI | |
|---|---|---|
Market Cap | $321.77B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $131.84 | $33.78 |
52-Week Low | $77.60 | $25.94 |
Enterprise Value | $368.53B | $46.16B |
Dividend Yield | 2.61% | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
VICI Properties trades at $26.07, down slightly by 0.02% on the day. The stock shows a bearish technical signal with moving averages indicating selling pressure, while fundamentals remain solid with a P/E of 10.07 and strong profitability margins. Recent Q2 2026 earnings missed EPS estimates but revenue beat, and the company raised its full-year AFFO guidance. A dividend of $0.45 per share was recently declared, supporting income appeal.
The outlook is mixed; analyst consensus is strongly bullish with a $29.83 price target, but near-term volatility exists due to the Caesars buyout overhang. The 6.6% dividend yield and balance sheet strength provide downside cushion, though high debt and interest expenses pose risks. Upside depends on execution of growth initiatives and stable cash flows from its real estate portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
